Chinese healthcare firms have been acquiring and investing in overseas pharmaceutical and medical device technologies at an astonishing pace over the past year. Here is a list of some of the notable deals done in the past month.
AK Medical Overseas Limited bought
JRI Orthopaedics Limited for HKD184 million (USD23 million).
Prenetics has acquired UK-based DNAFit to expand its global footprint and extend its reach in the consumer market.
China continues to be a hotbed of investment for U.S. pharmaceutical and biotech companies.
Shares of Adocia are up nearly 30 percent this morning after the French company announced it granted exclusive development and commercialization rights of its insulin products to Tonghua Dongbao Pharmaceuticals
Wuxi Biologics is to invest $392 million to build a new biologics drug substance manufacturing facility in Ireland.
Chinese drug maker Jiangsu Nhwa Pharmaceutical Co. has inked an agreement with US firm Trevena Inc.，a treatment for acute pain after surgery.
China’s CDH Investments $1.4 billion for Sirtex
China Luye Pharma bought the rights for Seroquel from AstraZeneca for $538 million.
Changshan Biochemical Pharma signed a $9.5 million deal to commercialize an osteoarthritis treatment in China developed by Israel’s Kitov Pharma.
Sinopharm Healthcare Fund lead the investment to Asun Biopharma for $85 million
Tonghua Dongbao Pharma acquired China rights to two diabetes treatments from Adocia of Lyon, France in an agreement worth up to $135 million.
